AGE - AgeX Therapeutics Inc Stock Price, Fair Value and News

8.70USD0.00 (0.00%)Delayed

Market Summary

USD8.700.00

Delayed

0.00%

AGE Stock Price

View Fullscreen

AGE RSI Chart

AGE Valuation

Market Cap

73.2M

Price/Earnings (Trailing)

-3.5

Price/Sales (Trailing)

515.5

EV/EBITDA

3.47

Price/Free Cashflow

-10.28

AGE Price/Sales (Trailing)

AGE Profitability

Operating Margin

71.83%

EBT Margin

10422.54%

Return on Equity

485.63%

Return on Assets

-192.76%

Free Cashflow Yield

-9.72%

AGE Fundamentals

AGE Revenue

Revenue (TTM)

142.0K

Rev. Growth (Yr)

600%

Rev. Growth (Qtr)

-16.42%

AGE Earnings

Earnings (TTM)

-20.9M

Earnings Growth (Yr)

-186.85%

Earnings Growth (Qtr)

-171.99%

Breaking Down AGE Revenue

Last 7 days

0.9%

Last 30 days

-28.1%

Last 90 days

-37.5%

Trailing 12 Months

-54.9%

How does AGE drawdown profile look like?

AGE Financial Health

Current Ratio

0.64

AGE Investor Care

Shares Dilution (1Y)

691.79%

Diluted EPS (TTM)

-15.59

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	39.0K	36.0K	71.3K	142.0K
2022	116.5K	89.0K	61.5K	34.0K
2021	306.8K	252.5K	198.3K	144.0K
2020	1.9M	1.5M	940.5K	361.0K
2019	1.5M	1.5M	1.5M	1.7M
2018	1.4M	1.4M	1.4M	1.4M
2017	0	0	0	1.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of AgeX Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 14, 2023	juvenescence ltd	gifted	-	-	-16,447,500	-
Mar 11, 2023	west michael d	sold (taxes)	-625	0.59	-1,060	chief executive officer
Mar 11, 2023	west michael d	acquired	-	-	3,125	chief executive officer
Dec 11, 2022	west michael d	sold (taxes)	-637	0.59	-1,081	chief executive officer
Dec 11, 2022	west michael d	acquired	-	-	3,125	chief executive officer
Sep 11, 2022	west michael d	sold (taxes)	-607	0.5623	-1,081	chief executive officer
Sep 11, 2022	west michael d	acquired	-	-	3,125	chief executive officer
Jun 11, 2022	west michael d	sold (taxes)	-832	0.7702	-1,081	chief executive officer
Jun 11, 2022	west michael d	acquired	-	-	3,125	chief executive officer
Mar 11, 2022	west michael d	sold (taxes)	-886	0.6923	-1,281	chief executive officer

Which funds bought or sold AGE recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	sold off	-100	-4,444	-	-%
May 15, 2024	CITADEL ADVISORS LLC	sold off	-100	-8,257	-	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	sold off	-100	-55,736	-	-%
May 15, 2024	BROADWOOD CAPITAL INC	sold off	-100	-1,153,900	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	sold off	-100	-4,130	-	-%
May 15, 2024	Prescott General Partners LLC	sold off	-100	-71,296	-	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-10.00	-	-%
May 15, 2024	MORGAN STANLEY	sold off	-100	-170	-	-%
May 15, 2024	STATE STREET CORP	sold off	-100	-10,318	-	-%
May 14, 2024	NORTHERN TRUST CORP	sold off	-100	-12,140	-	-%

Are Funds Buying or Selling AGE?

Are funds buying AGE calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AGE

No. of Funds

Unveiling AgeX Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 03, 2024	moreadith randall	6.8%	614,961	SC 13D
Mar 26, 2024	juvenescence ltd	81.4%	2,667,457	SC 13D/A
Mar 07, 2024	juvenescence ltd	81.1%	92,399,774	SC 13D/A
Feb 14, 2024	juvenescence ltd	81.0%	91,473,463	SC 13D/A
Feb 05, 2024	juvenescence ltd	80.6%	89,308,271	SC 13D/A
Jan 17, 2024	juvenescence ltd	80.4%	88,488,113	SC 13D/A
Jan 09, 2024	juvenescence ltd	80.2%	86,925,820	SC 13D/A
Dec 13, 2023	juvenescence ltd	80.4%	88,312,009	SC 13D/A
Nov 16, 2023	juvenescence ltd	79.4%	82,705,949	SC 13D/A
Nov 01, 2023	juvenescence ltd	79.2%	81,995,827	SC 13D/A

Recent SEC filings of AgeX Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 14, 2024	10-Q	Quarterly Report
May 14, 2024	8-K	Current Report
May 03, 2024	8-K	Current Report
May 03, 2024	S-1	Initial Public Offering
Apr 17, 2024	3	Insider Trading
Apr 17, 2024	4	Insider Trading
Apr 17, 2024	8-K	Current Report
Apr 04, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	3	Insider Trading

Peers (Alternatives to AgeX Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

AgeX Therapeutics Inc News

Latest updates

AgeX Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2
Revenue	-100.0%	-	56.00	67.00	38.00	9.00	10.00	8.00	9.00	12.00	5.00	18.00	31.00	43.00	56.00	52.00	49.00	45.00	515	549	411	380
Cost Of Revenue	-100.0%	-	1.00	33.00	-	5.00	1.00	1.00	5.00	6.00	1.00	1.00	2.00	13.00	3.00	5.00	17.00	3.00	1.00	79.00	49.00	53.00
Gross Profit	-100.0%	-	55.00	34.00	-	4.00	9.00	7.00	4.00	6.00	4.00	26.00	22.00	24.00	53.00	153	52.00	42.00	88.00	470	362	327
Operating Expenses	-35.7%	2,326	3,615	2,390	-	1,890	2,167	1,789	1,554	1,597	2,056	1,893	1,696	2,229	2,346	2,480	2,449	2,410	3,096	6,633	3,641	3,769
S&GA Expenses	-100.0%	-	3,433	2,172	-	1,730	1,993	1,581	1,392	1,338	1,660	1,517	1,421	1,748	2,022	1,575	1,796	1,475	1,875	1,717	2,194	2,119
R&D Expenses	507.7%	1,106	182	218	-	160	174	208	162	259	396	376	275	481	324	905	653	935	1,221	1,469	1,447	1,650
EBITDA Margin	-5.4%	135.92*	143.65*	160.36*	210.17*	416.44*	386.23*	427.47*	-108.49*	-76.73*	-65.26*	-47.84*	-44.64*	-37.30*	-	-	-	-	-	-	-	-
Interest Expenses	103.6%	1.00	-28.00	3,036	-	792	1,100	978	923	863	571	295	285	-	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	18.00	54.00	3.00
Earnings Before Taxes	-	-	-	-	-	-	-	18,261	-2,436	-2,618	-2,707	-2,262	-1,955	-2,475	-1,993	-3,137	-2,524	-2,432	-3,033	-2,723	-3,223	-3,152
EBT Margin	0%	104.23*	104.23*	98.44*	147.20*	291.67*	269.23*	308.82*	-162.98*	-107.21*	-80.68*	-60.31*	-48.22*	-40.11*	-	-	-	-	-	-	-	-
Net Income	-172.0%	-9,400	-3,456	-5,401	-	-2,669	-3,277	-2,703	-2,435	-2,618	-2,706	-2,158	-1,955	-2,474	-2,088	-2,446	-2,543	-2,689	-3,187	-2,711	-3,221	-3,089
Net Income Margin	-41.4%	-147.37*	-104.25*	-131.72*	-155.38*	-307.89*	-282.90*	-307.71*	-161.25*	-106.03*	-79.77*	-60.24*	-45.21*	-37.83*	-	-	-	-	-	-	-	-
Free Cashflow	21.3%	-1,614	-2,052	-1,864	-2,019	-2,019	-1,865	-1,321	-1,236	-1,746	-1,636	-1,647	-1,884	-1,694	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-9.3%	10,856	11,965	12,210	12,277	12,531	3,241	2,008	2,579	2,716	3,154	2,427	2,541	3,160	3,925	4,203	4,757	5,092	7,442	8,183	10,257	12,321
Current Assets	1085.3%	8,937	754	1,141	1,350	1,747	2,453	1,187	1,725	1,829	2,234	1,475	1,556	2,142	2,283	1,929	2,104	2,072	4,054	4,690	6,680	9,648
Cash Equivalents	2421.7%	8,700	345	397	261	280	645	466	702	448	584	731	615	809	527	1,107	1,033	468	2,352	3,768	5,813	8,586
Net PPE	-1.6%	564	573	-	-	-	-	-	-	-	-	-	-	-	-	442	681	898	1,126	1,010	951	84.00
Liabilities	129.5%	15,165	6,607	3,897	34,573	32,536	20,556	17,157	15,841	14,307	15,029	12,405	10,835	9,263	9,321	7,949	6,879	5,467	4,825	3,240	2,850	2,294
Current Liabilities	137.7%	14,059	5,914	3,204	24,505	22,525	10,078	8,809	9,085	10,099	8,967	6,598	5,271	3,929	5,357	4,854	4,713	5,467	3,297	2,907	2,629	-
Shareholder's Equity	-178.8%	-4,309	5,469	-	-	-36,118	-37,778	-	-	-	-11,875	-	-	-	-	-	-	-	2,617	4,943	7,407	10,027
Retained Earnings	95.9%	-5,435	-131,000	-127,557	-122,200	-119,487	-116,210	-113,507	-111,072	-108,500	-105,748	-103,590	-101,600	-99,161	-97,073	-94,627	-92,084	-89,395	-86,208	-83,497	-80,276	-77,187
Additional Paid-In Capital	-99.2%	1,125	136,482	100,017	99,977	99,589	98,998	98,399	97,850	96,903	93,912	93,650	93,379	93,095	91,810	90,880	89,555	88,608	88,353	87,758	86,975	86,480
Shares Outstanding	679.8%	8,414	1,079	1,063	1,063	1,063	1,079	1,063	1,062	1,062	1,062	1,060	1,062	-	-	-	-	-	-	-	-	-
Minority Interest	100.0%	-	-111	-109	-121	-111	-103	-45.00	-44.00	-44.00	-43.00	-42.00	-42.00	-41.00	-280	-95.00	322	364	399	604	660	706
Float	-	-	-	-	18,700	-	-	-	12,100	-	-	-	32,500	-	-	-	19,600	-	-	-	56,400	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	22.0%	-1,600	-2,052	-1,864	-2,019	-1,865	-1,321	-1,236	-1,746	-1,636	-1,647	-1,884	-1,694	-2,630	-1,620	-1,889	-2,244	-2,064	-2,411	-2,372	-2,759	-2,618
Share Based Compensation	-89.5%	53.00	503	40.00	35.00	70.00	114	209	198	239	263	272	286	178	178	227	252	252	420	491	515	481
Cashflow From Investing	-Infinity%	-14.00	-	-	-	-10,000	-	-	-	-	-	-	-	666	-	-12.00	-4.00	-4.00	-295	-157	94.00	-3.00
Cashflow From Financing	36.4%	2,728	2,000	2,000	2,000	11,500	1,500	1,000	2,000	1,500	1,500	2,000	1,500	2,246	992	1,977	2,807	185	1,287	487	-9.00	4,500

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

AGE Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
REVENUES
Total revenues	$ 5	$ 30
OPERATING EXPENSES
Research and development	1,106	399
General and administrative	1,220	593
Total operating expenses	2,326	992
Loss from operations	(2,321)	(962)
OTHER INCOME (EXPENSE), NET:
Interest expense, net	(99)	(86)
Fair value inception adjustment on convertible promissory note		2,240
Change in fair value of convertible promissory notes	(7,017)	294
Change in fair value of warrants		172
Total other income (expense), net	(7,116)	2,620
NET INCOME (LOSS)	$ (9,437)	$ 1,658
NET EARNINGS (LOSS) PER COMMON SHARE:
BASIC	$ (3.38)	$ 0.77
DILUTED	$ (3.38)	$ 0.20
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING:
BASIC	2,790	2,167
DILUTED	2,790	8,569
Grant Revenues [Member]
REVENUES
Total revenues	$ 5	$ 30

AGE Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 8,706	$ 7,619
Accounts and grants receivable, net	65
Prepaid expenses and other current assets	166
Total current assets	8,937	7,619
Restricted cash	50
Property and equipment, net	564	573
Right of use assets - operating leases	627	666
Right of use assets - finance leases	104	110
Intangible assets, net	574
TOTAL ASSETS	10,856	8,968
Current liabilities:
Accounts payable and accrued liabilities	4,013	1,163
Loans due to Juvenescence, net of debt issuance costs	9,746
Current portion of operating lease liabilities	207	214
Current portion of finance lease liabilities	24	36
Total current liabilities	14,059	1,413
Loans due to Juvenescence	693
Convertible promissory notes, at fair value		2,983
Operating lease liabilities, net of current portion	413	461
Finance lease liabilities, net of current portion		1
TOTAL LIABILITIES	15,165	4,858
Commitments and contingencies (Note 11)
Redeemable Convertible Preferred Stock:
Temporary stock, stated value		36,404
Stockholders’ deficit:
Preferred stock value
Common stock, $0.0001 par value, 40,000 shares authorized; and 8,414 and 2,410 shares issued and outstanding	1	25
Additional paid-in capital	1,125	858
Accumulated deficit	(5,435)	(33,177)
Total stockholders’ deficit	(4,309)	(32,294)
TOTAL LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS’ DEFICIT	10,856	8,968
Redeemable Convertible Preferred Stock [Member]
Redeemable Convertible Preferred Stock:
Temporary stock, stated value		36,404
Related Party [Member]
Current liabilities:
Other current liabilities	66
Nonrelated Party [Member]
Current liabilities:
Other current liabilities	$ 3

About AgeX Therapeutics Inc

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead small molecule drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550 (Renelon), a gene delivery technology. AgeX Therapeutics, Inc. has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. The company was incorporated in 2017 and is based in Alameda, California.

CEO	Dr. Joanne M. Hackett Ph.D.
WEBSITE	agexinc.com
INDUSTRY	Biotechnology
EMPLOYEES	5

AgeX Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for AgeX Therapeutics Inc? What does AGE stand for in stocks?

AGE is the stock ticker symbol of AgeX Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of AgeX Therapeutics Inc (AGE)?

As of Fri May 17 2024, market cap of AgeX Therapeutics Inc is 73.2 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AGE stock?

You can check AGE's fair value in chart for subscribers.

What is the fair value of AGE stock?

You can check AGE's fair value in chart for subscribers. The fair value of AgeX Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of AgeX Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AGE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is AgeX Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether AGE is over valued or under valued. Whether AgeX Therapeutics Inc is cheap or expensive depends on the assumptions which impact AgeX Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AGE.

What is AgeX Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, AGE's PE ratio (Price to Earnings) is -3.5 and Price to Sales (PS) ratio is 515.5. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AGE PE ratio will change depending on the future growth rate expectations of investors.